Sandra Pritzkow et al., 2024-09-04: Screening study using protein misfolding cyclic amplification: methylene blue was the only compound tested that completely blocked prion replication across human, cattle, cervid and mouse prions, with an IC50 of 7.7 micromolar for vCJD prions.
only one of these compounds (methylene blue) was able to completely inhibit prion replication in all species. Estimation of the IC50 for methylene blue inhibition of human prions causing variant Creutzfeldt-Jakob disease (vCJD) was 7.7 μM.
Abstract
Sandra Pritzkow et al., 2024-09-04: Screening study using protein misfolding cyclic amplification: methylene blue was the only compound tested that completely blocked prion replication across human, cattle, cervid and mouse prions, with an IC50 of 7.7 micromolar for vCJD prions. Laboratory study (PMCA amplification of prions from four species; no animals or humans dosed). Country: United States (University of Texas Health Science Center at Houston, McGovern Medical School). Concentration: IC50 7.7 microM for vCJD prions; other values in full text. Route: in vitro. Funder: NIH P01 AI077774 and R01 AI132695. Conflicts: substantial and declared – Claudio Soto is founder/CSO and board member of Amprion Inc., Sandra Pritzkow also has a conflict, the University of Texas has licensed patents to Amprion, and Rodrigo Morales is an inventor on a PMCA patent. Comparator: untreated prion amplification; a panel of other candidate anti-prion compounds. This is 'other protein aggregation' evidence and it is the strongest single result in that group – but it is in vitro amplification, not disease. Study type: lab.
